Core Viewpoint - China High Precision (00591.HK) reported a significant decline in revenue and profit for the six months ending December 31, 2025, primarily due to reduced sales in industrial automation instruments and increased foreign exchange losses [1] Financial Performance - The group's revenue for the period was approximately RMB 85.48 million, representing a decrease of about 26.5% compared to the same period in 2024 [1] - Profit attributable to the company's owners was approximately RMB 3.788 million, down from RMB 15.81 million in the same period of 2024 [1] - Basic and diluted earnings per share were RMB 0.37, compared to RMB 1.52 for the six months ending December 31, 2024 [1] Revenue Drivers - The decline in revenue was mainly attributed to project delays that led to reduced sales of industrial automation instruments in the oil and petrochemical sectors [1] - This decline was partially offset by slight growth in contract manufacturing services for automation instruments and technical products [1] Market Challenges - The company continues to face multiple challenges in the industrial automation instrument sector due to the slowdown in economic growth and global economic uncertainties [1]

Core Insights - The company reported a total operating revenue of 876.18 million yuan for the fiscal year 2025, representing a year-on-year decline of 7.93% [1] - The net profit attributable to the parent company was -62.54 million yuan, a significant decrease of 327.94% compared to the previous year [1] - The net profit attributable to the parent company, excluding non-recurring gains and losses, was -77.65 million yuan, reflecting a staggering decline of 996.98% year-on-year [1] Business Performance - The core network system business experienced growth, driven by positive developments in emerging fields such as satellite internet and 5G, leading to a steady increase in product orders [1] - Traditional communication business faced significant pressure, with overall revenue and gross margin declining due to intensified competition in the domestic and international operator bidding markets [1] - The coal industry's supply-demand dynamics negatively impacted the company's traditional communication business, particularly in the optical network and access system segments, which saw a substantial decline in sales [1]

Group 1 - The company China High Precision (00591.HK) announced the appointment of independent non-executive director Chen Yuxiao as the chief independent non-executive director, effective from February 27, 2026 [1]

Group 1 - The company Qin Chuan Machine Tool (000837.SZ) has received special funds for state-owned enterprise reform and development, which will be injected as capital by its controlling shareholder, Shaanxi Fast Group [1][2] - The funds are allocated based on notifications from the Shaanxi Provincial Finance Department and the State-owned Assets Supervision and Administration Commission, specifically for the years 2020 and 2025 [1] - As of the announcement date, the company has received a total of 31 million yuan from the controlling shareholder as capital injection [2] Group 2 - The company will disclose information upon receiving each tranche of the allocated funds and will convert these funds into capital from the controlling shareholder during future share issuance [2] - The actual amount and timing of the fund disbursement will be based on notifications from the upper-level government units [2]

Core Viewpoint - The resignation of the executive director and changes in the board composition are aimed at allowing the departing director to focus on other business ventures, while the new appointee is set to take on multiple roles within the company [1] Group 1 - The company announced that萧若虹 will resign from the position of executive director, member of the remuneration committee, and chairman of the nomination committee, effective from March 1, 2026 [1] - 徐家健 will be appointed as the executive director, chairman of the nomination committee, and member of the remuneration committee, also effective from March 1, 2026 [1]

Core Viewpoint - The company has entered into a joint venture agreement with Fair Price Group to establish Gohan Concepts Pte.Ltd., focusing on premium Japanese dining concepts in Singapore [1] Group 1: Joint Venture Details - The joint venture will see the company’s subsidiary holding 49% and Fair Price Group holding 51% of the equity in Gohan Concepts Pte.Ltd. [1] - The joint venture will operate as an associate company and will not be consolidated into the group’s financial results [1] Group 2: Strategic Rationale - Fair Price Group possesses a vast retail network and operational capabilities in Singapore, which will complement the company’s expertise in Japanese brand franchising [1] - The collaboration aims to leverage the company’s extensive experience in brand introduction and franchise management to develop and operate selected premium Japanese dining brands [1]

报告期内，在人工智能技术发展持续拉动光芯片需求增长的背景下，公司基于技术积累和产品性能，优 化资源配置，提升资源投入效率和经营质量，数据中心领域CW光源产品销售额实现大幅度增长，同时 数据中心产品毛利率水平高于电信市场，上述因素推动公司收入及利润实现增长。电信业务板块经营情 况基本保持稳定。 格隆汇2月27日丨源杰科技(688498.SH)公布2025年度业绩快报，报告期，公司营业收入为6.01亿元，同 比增幅为138.50%；归属于母公司所有者的净利润为1.91亿元。 ...

Core Viewpoint - The shareholder Lu Yu of Jing Sheng Co., Ltd. (688478.SH) plans to reduce his stake in the company due to personal funding needs, with a maximum reduction of 4.1509 million shares [1] Summary by Category Shareholder Actions - Lu Yu intends to reduce his holdings by up to 1.3836 million shares through centralized bidding, which represents no more than 1% of the company's total share capital [1] - Additionally, he plans to reduce up to 2.7673 million shares through block trading, accounting for no more than 2% of the company's total share capital [1] Implementation Timeline - The reduction plan will be implemented within three months starting from 15 trading days after the announcement date [1] Pricing Details - The minimum selling price for the shares is set at 32.52 yuan per share [1]

Core Viewpoint - The approval of the non-covalent BTK inhibitor, Pirtobrutinib (捷帕力®), for a new indication in China represents a significant advancement for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have previously undergone treatment with BTK inhibitors [1][2] Group 1: Approval and Indication - Pirtobrutinib has received approval from the National Medical Products Administration (NMPA) in China for the treatment of adult patients with CLL/SLL who have previously received at least one systemic therapy including a BTK inhibitor [1] - The drug was previously approved by the FDA in January 2023 and is indicated for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two systemic therapies, including BTK inhibitors, by October 2024 in China [1] Group 2: Clinical Study Results - The approval is based on the results of the international, multicenter, randomized controlled BRUIN-CLL-321 Phase III study, which included 238 patients previously treated with covalent BTK inhibitors [2] - Pirtobrutinib significantly extended the median progression-free survival (PFS) to 14.0 months compared to 8.7 months for the control group (HR=0.54) and had a lower treatment-related discontinuation rate of 5.2% versus 21.1% [2] Group 3: Market Impact and Strategy - The approval of Pirtobrutinib for CLL/SLL in China is a major breakthrough, allowing local patients to benefit from this global innovation [2] - The company aims to leverage its leading brand and expertise in the oncology field to accelerate the accessibility of this innovative therapy for more patients in need [2]

Group 1 - The company, Yidu Tech (02158.HK), announced a share buyback on February 27, spending HKD 1.927 million to repurchase 322,000 shares [1]